Omeros Corp (OMER) stock
OMERNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.49−0.50 (-2.78%)
Close on Nov 13, 2026Market cap $1.27BP/E –Yield –
Omeros r&d expenses
Research and development expenses are spending on new products and technology.
Omeros's R&D Expenses for the twelve months ending Jun 30, 2026 was $62.60M, down 32.9% year over year. For fiscal 2025 it was $81.30M, down 32.0% from the year before. Over ten years it grew 5.3% a year on average. The highest annual figure on record is $119.52M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.30M | -32.0% |
| FY2024 | Dec 31, 2024 | $119.52M | +4.1% |
| FY2023 | Dec 31, 2023 | $114.87M | +1.9% |
| FY2022 | Dec 31, 2022 | $112.72M | -5.1% |
| FY2021 | Dec 31, 2021 | $118.78M | +10.4% |
| FY2020 | Dec 31, 2020 | $107.61M | +1.2% |
| FY2019 | Dec 31, 2019 | $106.32M | +18.3% |
| FY2018 | Dec 31, 2018 | $89.86M | +61.6% |
| FY2017 | Dec 31, 2017 | $55.60M | +9.7% |
| FY2016 | Dec 31, 2016 | $50.70M | +4.8% |
| FY2015 | Dec 31, 2015 | $48.38M | +0.9% |
| FY2014 | Dec 31, 2014 | $47.95M | +32.1% |
| FY2013 | Dec 31, 2013 | $36.30M | +13.7% |
| FY2012 | Dec 31, 2012 | $31.92M | +34.6% |
| FY2011 | Dec 31, 2011 | $23.72M | +1.1% |
| FY2010 | Dec 31, 2010 | $23.47M | +38.6% |
| FY2009 | Dec 31, 2009 | $16.93M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.80M | -37.3% |
| Q1 FY2026 | Mar 31, 2026 | $13.36M | -44.0% |
| Q4 FY2025 | Dec 31, 2025 | $19.45M | -16.6% |
| Q3 FY2025 | Sep 30, 2025 | $16.00M | -33.6% |
| Q2 FY2025 | Jun 30, 2025 | $22.01M | -51.5% |
| Q1 FY2025 | Mar 31, 2025 | $23.85M | -10.9% |
| Q4 FY2024 | Dec 31, 2024 | $23.32M | -19.3% |
| Q3 FY2024 | Sep 30, 2024 | $24.08M | -24.1% |
| Q2 FY2024 | Jun 30, 2024 | $45.35M | +53.0% |
| Q1 FY2024 | Mar 31, 2024 | $26.77M | +8.8% |
| Q4 FY2023 | Dec 31, 2023 | $28.89M | +8.8% |
| Q3 FY2023 | Sep 30, 2023 | $31.73M | -17.7% |
| Q2 FY2023 | Jun 30, 2023 | $29.64M | +26.0% |
| Q1 FY2023 | Mar 31, 2023 | $24.61M | +2.2% |
| Q4 FY2022 | Dec 31, 2022 | $26.55M | -12.5% |
| Q3 FY2022 | Sep 30, 2022 | $38.57M | +18.7% |
| Q2 FY2022 | Jun 30, 2022 | $23.52M | +1.1% |
| Q1 FY2022 | Mar 31, 2022 | $24.09M | -23.1% |
| Q4 FY2021 | Dec 31, 2021 | $30.33M | +25.7% |
| Q1 FY2021 | Mar 31, 2021 | $32.50M | +12.4% |
| Q4 FY2020 | Dec 31, 2020 | $23.25M | -37.5% |
| Q3 FY2020 | Sep 30, 2020 | $31.32M | +31.9% |
| Q2 FY2020 | Jun 30, 2020 | $24.13M | +26.3% |
| Q1 FY2020 | Mar 31, 2020 | $28.91M | +10.1% |
| Q4 FY2019 | Dec 31, 2019 | $37.22M | +46.3% |
| Q3 FY2019 | Sep 30, 2019 | $23.75M | -11.6% |
| Q2 FY2019 | Jun 30, 2019 | $19.11M | -1.6% |
| Q1 FY2019 | Mar 31, 2019 | $26.26M | +44.7% |
| Q4 FY2018 | Dec 31, 2018 | $25.45M | +65.4% |
| Q3 FY2018 | Sep 30, 2018 | $26.86M | +81.1% |
| Q2 FY2018 | Jun 30, 2018 | $19.41M | +47.8% |
| Q1 FY2018 | Mar 31, 2018 | $18.14M | +48.2% |
| Q4 FY2017 | Dec 31, 2017 | $15.39M | +22.7% |
| Q3 FY2017 | Sep 30, 2017 | $14.84M | +18.8% |
| Q2 FY2017 | Jun 30, 2017 | $13.14M | +28.4% |
| Q1 FY2017 | Mar 31, 2017 | $12.24M | – |
| Q4 FY2016 | Dec 31, 2016 | $12.54M | – |
| Q3 FY2016 | Sep 30, 2016 | $12.49M | – |
| Q2 FY2016 | Jun 30, 2016 | $10.23M | – |
See a number that looks wrong?